diltiazem has been researched along with Benign Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Bajpai, SK; Edwina, P; Roy, B; Sivasubramaniapandian, M; Vaibavi, SR; Vaippully, R | 1 |
| Lewis, KL; Lin, C; Mundra, V; Novotny, W; Opat, S; Ou, YC; Sahasranaman, S; Stern, JC; Tariq, B; Walker, P; Wong Doo, N | 1 |
| Cai, M; Huang, M; Jiang, L; Li, H; Li, J; Shang, L; Song, M; Xie, D; Xie, S; Xu, P; Yan, S; Yu, S; Yuan, C; Zhou, Y | 1 |
| Behar, S; Boyko, V; Braun, S; Goldbourt, U; Kaplinsky, E; Laniado, S; Reicher-Reiss, H | 1 |
| Ishikawa, K; Kanamasa, K; Kimura, A; Miyataka, M; Takenaka, T | 1 |
| Bennewith, KL; Durand, RE | 1 |
| Baumelou, A; Bourbouze, R; Cacoub, P; Deray, G; Jacobs, C; Jacquillat, C; Khayat, D; Musset, L | 1 |
3 trial(s) available for diltiazem and Benign Neoplasms
| Article | Year |
|---|---|
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Fluconazole; Humans; Neoplasms; Voriconazole | 2023 |
Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem. Secondary Prevention Group.
Topics: Calcium Channel Blockers; Cause of Death; Diltiazem; Female; Humans; Male; Middle Aged; Myocardial Infarction; Neoplasms; Nifedipine; Odds Ratio; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 1999 |
The effects of diltiazem on methotrexate-induced nephrotoxicity.
Topics: Acute Kidney Injury; Adult; Diltiazem; Diuresis; Drug Interactions; Humans; Kidney Function Tests; Methotrexate; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic | 1989 |
4 other study(ies) available for diltiazem and Benign Neoplasms
| Article | Year |
|---|---|
Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells.
Topics: Calcium; Calcium Channel Blockers; Diltiazem; Endothelial Cells; Neoplasms; Nifedipine; Verapamil | 2022 |
Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor.
Topics: Diltiazem; Glyburide; Humans; Ligands; Neoplasms; Urokinase-Type Plasminogen Activator | 2023 |
Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group.
Topics: Aged; Calcium Channel Blockers; Cause of Death; Confidence Intervals; Coronary Disease; Diltiazem; Female; Humans; Male; Middle Aged; Neoplasms; Nifedipine; Odds Ratio; Risk Factors; Verapamil | 1998 |
Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity.
Topics: Animals; Calcium Channel Blockers; Diltiazem; Dose-Response Relationship, Drug; Flow Cytometry; Hematologic Agents; Humans; Kinetics; Mice; Neoplasms; Pentoxifylline; Perfusion; Radiation Tolerance; Regional Blood Flow; Rubidium Radioisotopes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |